Published in Eur J Pharmacol on July 23, 2010
Diabetes recovery by age-dependent conversion of pancreatic δ-cells into insulin producers. Nature (2014) 2.19
Expanded granulocyte/monocyte compartment in myeloid-specific triple FoxO knockout increases oxidative stress and accelerates atherosclerosis in mice. Circ Res (2013) 0.91
FOXO1 inhibition yields functional insulin-producing cells in human gut organoid cultures. Nat Commun (2014) 0.87
Adamts1 mediates ethanol-induced alterations in collagen and elastin via a FoxO1-sestrin3-AMPK signaling cascade in myocytes. J Cell Biochem (2015) 0.80
Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. Nat Rev Drug Discov (2016) 0.80
S-adenosylmethionine-dependent protein methylation is required for expression of selenoprotein P and gluconeogenic enzymes in HepG2 human hepatocytes. J Biol Chem (2012) 0.78
OutFOXing myeloid cells in atherosclerosis with FoxOs. Circ Res (2013) 0.75
FoxO1-AMPK-ULK1 Regulates Ethanol-Induced Autophagy in Muscle by Enhanced ATG14 Association with the BECN1-PIK3C3 Complex. Alcohol Clin Exp Res (2017) 0.75
Effects of low-intensity prolonged exercise on PGC-1 mRNA expression in rat epitrochlearis muscle. Biochem Biophys Res Commun (2002) 2.75
The brain-specific carnitine palmitoyltransferase-1c regulates energy homeostasis. Proc Natl Acad Sci U S A (2006) 1.77
Ultrasound-guided radial artery catheterization in infants and small children. Pediatr Crit Care Med (2013) 1.49
Differential effects of a centrally acting fatty acid synthase inhibitor in lean and obese mice. Proc Natl Acad Sci U S A (2002) 1.40
Phosphodiesterase 3 inhibition reduces platelet activation and monocyte tissue factor expression in knee arthroplasty patients. Anesthesiology (2009) 1.39
Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Mol Pharmacol (2010) 1.38
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol (2013) 1.14
Brain-specific carnitine palmitoyl-transferase-1c: role in CNS fatty acid metabolism, food intake, and body weight. J Neurochem (2008) 1.13
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol (2011) 1.09
Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo. Biochem Pharmacol (2006) 1.07
Hypoglycaemic effects of antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic rats. Basic Clin Pharmacol Toxicol (2008) 1.03
Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J Pharmacol Sci (2012) 1.00
Efficient delivery of siRNA using dendritic poly(L-lysine) for loss-of-function analysis. J Control Release (2007) 0.98
Ultrasound evidence of the optimal wrist position for radial artery cannulation. Can J Anaesth (2009) 0.95
SHIP2 and its involvement in various diseases. Expert Opin Ther Targets (2010) 0.94
Application of fluorescent cholangiography to single-incision laparoscopic cholecystectomy. Surg Endosc (2011) 0.94
Effects of antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice. Eur J Pharmacol (2011) 0.91
Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction. Transpl Immunol (2010) 0.91
A role of androgen receptor protein in cell growth of an androgen-independent prostate cancer cell line. Biosci Biotechnol Biochem (2005) 0.87
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol (2014) 0.87
AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes. Biochem Biophys Res Commun (2010) 0.87
Enhanced insulin secretion and sensitization in diabetic mice on chronic treatment with a transient receptor potential vanilloid 1 antagonist. Life Sci (2011) 0.86
Fluorescence navigation hepatectomy by visualization of localized cholestasis from bile duct tumor infiltration. J Am Coll Surg (2010) 0.84
Safe and efficient methods of autologous hematopoietic stem cell transplantation for biomedical research in cynomolgus monkeys. Comp Med (2002) 0.84
FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC). I. Taxonomy, fermentation, isolation and biological activities. J Antibiot (Tokyo) (2003) 0.84
Effects of high glucose on AVP-induced hyperplasia, hypertrophy, and type IV collagen synthesis in cultured rat mesangial cells. Endocr Res (2012) 0.83
FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase III. Structure determination. J Antibiot (Tokyo) (2003) 0.83
Peripheral sensitization caused by insulin-like growth factor 1 contributes to pain hypersensitivity after tissue injury. Pain (2011) 0.83
YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin Cancer Res (2006) 0.83
Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice. Metabolism (2009) 0.82
A novel method for ultrasound-guided radial arterial catheterization in pediatric patients. Anesth Analg (2014) 0.82
Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion. J Pharmacol Exp Ther (2013) 0.82
Vasopressin increases type IV collagen production through the induction of transforming growth factor-beta secretion in rat mesangial cells. Pharmacol Res (2008) 0.81
Vasopressin induces human mesangial cell growth via induction of vascular endothelial growth factor secretion. Neuropeptides (2010) 0.81
Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice. Biochem Biophys Res Commun (2010) 0.81
Collection and analysis of hematopoietic progenitor cells from cynomolgus macaques (Macaca fascicularis): assessment of cross-reacting monoclonal antibodies. Am J Primatol (2003) 0.80
Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.80
Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. Biochem Biophys Res Commun (2010) 0.80
Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.80
Glucose metabolism activation by SHIP2 inhibitors via up-regulation of GLUT1 gene in L6 myotubes. Eur J Pharmacol (2010) 0.80
Diclofenac, a non-steroidal anti-inflammatory drug, suppresses apoptosis induced by endoplasmic reticulum stresses by inhibiting caspase signaling. Neuropharmacology (2006) 0.80
Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist. Vascul Pharmacol (2005) 0.80
Prevention of immune responses to human erythropoietin in cynomolgus monkeys (Macaca fascicularis). J Vet Med Sci (2006) 0.79
Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors. Pharmacol Res (2005) 0.79
The RACHS-1 risk category can be a predictor of perioperative recovery in Asian pediatric cardiac surgery patients. J Anesth (2013) 0.79
Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice. Eur J Pharmacol (2009) 0.79
RMI1 deficiency in mice protects from diet and genetic-induced obesity. FEBS J (2009) 0.79
Differences in gene expression profile among SH-SY5Y neuroblastoma subclones with different neurite outgrowth responses to nerve growth factor. J Neurochem (2005) 0.79
Protective effect of FK506 against apoptosis of SH-SY5Y cells correlates with regulation of the serum inducible kinase gene. Biochem Pharmacol (2005) 0.78
Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy. Vascul Pharmacol (2007) 0.78
Safe and efficient collection of cytokine-mobilized peripheral blood cells from cynomolgus monkeys (Macaca fascicularis) with human newborn-equivalent body weights. Exp Anim (2005) 0.78
Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors. Pharmacol Rep (2009) 0.78
Novel GPR119 agonist AS1669058 potentiates insulin secretion from rat islets and has potent anti-diabetic effects in ICR and diabetic db/db mice. Life Sci (2012) 0.78
The novel hypoglycemic agent YM440 improves hepatic insulin resistance in obese Zucker fatty rats. J Pharmacol Sci (2006) 0.77
Adipocyte hyperplasia and RMI1 in the treatment of obesity. FEBS J (2010) 0.77
ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity. Biochem Pharmacol (2008) 0.77
Binding and signal transduction characteristics of the nonpeptide vasopressin V1A receptor-selective antagonist YM218 in cultured rat mesangial cells. Pharmacology (2006) 0.77
Effects of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells. Eur J Pharmacol (2006) 0.77
YM-201627: an orally active antitumor agent with selective inhibition of vascular endothelial cell proliferation. Cancer Lett (2005) 0.77
Hypoglycemic agent YM440 suppresses hepatic glucose output via gluconeogenesis by reducing glucose-6-phosphatase activity in obese Zucker rats. Eur J Pharmacol (2003) 0.77
Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation. Biochem Pharmacol (2003) 0.77
Glucose regulates RMI1 expression through the E2F pathways in adipose cells. Endocrine (2011) 0.76
CyclinB2 and BIRC5 genes as surrogate biomarkers for neurite outgrowth in SH-SY5Y subclonal cells. Neuropharmacology (2006) 0.76
Effect of vasopressin on type IV collagen production in human mesangial cells. Regul Pept (2008) 0.76
Retracted Human expanded polyglutamine androgen receptor mutants in neurodegeneration as a novel ligand target. J Pharmacol Exp Ther (2005) 0.76
Emerging targets for the treatment of obesity. FEBS J (2010) 0.75
Splenic Marginal Zone Lymphoma with Acquired von Willebrand Syndrome Diagnosed via Splenic Bleeding. Intern Med (2017) 0.75
Vasopressin regulates rat mesangial cell growth by inducing autocrine secretion of vascular endothelial growth factor. J Physiol Sci (2011) 0.75
[Selection of pediatric endotracheal tube size by ultrasonography]. Masui (2011) 0.75
YM440, a novel hypoglycemic agent, protects against nephropathy in Zucker fatty rats via plasma triglyceride reduction. Eur J Pharmacol (2006) 0.75
Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice. Pharmacology (2009) 0.75
Effects of angiotensin II type 1 receptor antagonist, YM358, on cardiac hypertrophy and dysfunction after myocardial infarction in rats. Biol Pharm Bull (2002) 0.75
[Case report of TGA-1 neonate with hyponatremia]. Masui (2011) 0.75
Downregulation of vasopressin V1A receptors and activation of mitogen-activated protein kinase in rat mesangial cells cultured under high-glucose conditions. Clin Exp Pharmacol Physiol (2012) 0.75
Myonase is localized in skeletal muscle myofibrils. J Biochem (2002) 0.75
Mass-tag technology for monitoring of protein kinase activity using mass spectrometry. Bioorg Med Chem Lett (2004) 0.75
Hypoglycemic agent YM440 ameliorates the impaired hepatic glycogenesis after glucose loading by increasing glycogen synthase activity in obese Zucker rats. Jpn J Pharmacol (2002) 0.75
[A multicenter survey of pediatric endotracheal tube management]. Masui (2015) 0.75
YM-231146, a novel orally bioavailable inhibitor of vascular endothelial growth factor receptor-2, is effective against paclitaxel resistant tumors. Biol Pharm Bull (2005) 0.75
Intraoperative monitoring of movement of an entrapped coronary guidewire by transesophageal echocardiography. Anesth Analg (2008) 0.75
Vasopressin stimulates the production of extracellular matrix by cultured rat mesangial cells. Clin Exp Pharmacol Physiol (2007) 0.75
Acute development of superior vena cava syndrome after pediatric cardiac surgery. Paediatr Anaesth (2008) 0.75
High-level in vivo gene marking after gene-modified autologous hematopoietic stem cell transplantation without marrow conditioning in nonhuman primates. Mol Ther (2004) 0.75